Drug approvals 2011: focus on companion diagnostics.
Merrill
M
Goozner
D000736:Androstenes; D000737:Androstenols / Q000494:pharmacology; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000077784:Axitinib; D014408:Biomarkers, Tumor / Q000378:metabolism*; D000079963:Brentuximab Vedotin; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000378:metabolism; D002986:Clinical Trials as Topic; D000077547:Crizotinib; D017277:Drug Approval / Q000379:methods; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D018796:Immunoconjugates / Q000494:pharmacology; D007191:Indazoles / Q000494:pharmacology; D007211:Indoles / Q000494:pharmacology; D000074324:Ipilimumab; D008175:Lung Neoplasms / Q000188:drug therapy / Q000378:metabolism; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000378:metabolism; D058990:Molecular Targeted Therapy / Q000379:methods; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D010880:Piperidines / Q000494:pharmacology; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000378:metabolism; D011720:Pyrazoles / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D011799:Quinazolines / Q000494:pharmacology; D035583:Rare Diseases / Q000188:drug therapy / Q000378:metabolism; D013449:Sulfonamides / Q000494:pharmacology; D016019:Survival Analysis; D014481:United States; D014486:United States Food and Drug Administration; D000077484:Vemurafenib
D000736:Androstenes; D000737:Androstenols; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D007093:Imidazoles; D018796:Immunoconjugates; D007191:Indazoles; D007211:Indoles; D000074324:Ipilimumab; D010880:Piperidines; D011720:Pyrazoles; D011725:Pyridines; D011799:Quinazolines; D013449:Sulfonamides; D000077484:Vemurafenib; D000077547:Crizotinib; D000079963:Brentuximab Vedotin; D000077784:Axitinib; C089740:abiraterone; C452423:vandetanib